Pasadena Bio-Tech Adds Industry Veteran Board Director As Its Novel Anti-Cancer Compound Enters Clinical Development Phase

A new Board Director has been appointed to a Pasadena bio-tech company now in the clinical phase of the development of a novel anti-cancer compound as a major new addition to chemotherapy and immunotherapy regimens.

LIXTE Biotechnology Holdings, Inc., has appointed industry veteran Bas van der Baan as an independent director.

Educated in the Netherlands, van der Baan has a Master of Science degree from Wageningen University and Research and was at one time Board Member of the Amsterdam Economic Board. Before coming to LIXTE, he was Chief Clinical and Business Development Officer at Agendia, Inc., with offices in Irvine and in the Netherlands.

LIXTE is now in the clinical phase of development of LB-100, its first-in-class protein phosphatase 2A (PP2A) inhibitor, according to Founder and CEO Dr. John S. Kovach.

“Our goal is to demonstrate the potential of this novel anti-cancer compound as a major new addition to chemotherapy and immunotherapy regimens. Mr. van der Baan will bring substantial experience and expertise in the commercialization of new modalities in the oncology market to our Board of Directors as we continue the clinical development of LB-100,” Kovach said.

LIXTE Biotechnology Holdings, Inc., whose offices are at 680 E Colorado Blvd. in Pasadena, said it has achieved a breakthrough with LB-100, its novel first-in-class lead clinical compound and PP2A inhibitor, and has demonstrated that the drug is readily tolerated in cancer patients at doses associated with anti-cancer activity.

“LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE’s new approach has no known competitors and is covered by a comprehensive patent portfolio,” the company said. “Initial proof-of-concept clinical trials are in progress.”

To learn more about LIXTE, visit www.lixte.com.